Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (181-190 of 346) with videos related to

Pageof 35
Sort By:
Leukemia|April 12, 2022
Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinibYuya Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Cancer|April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinibKiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2024
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeOren Pasvolsky, Rima M Saliba, Uday R Popat, et al.
Blood Cancer Journal|May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotypeBachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
Cancer|October 12, 2018
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageElias Jabbour, Koji Sasaki, Farhad Ravandi, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
The Lancet. Haematology|September 20, 2024
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trialNicholas J Short, Daniel Nguyen, Elias Jabbour, et al.
American Journal of Hematology|April 24, 2026
Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score AnalysisKoji Sasaki, Hagop Kantarjian, Caitlin R Rausch, et al.
Blood Advances|November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemiaNicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Pageof 35

Showing results (181-190 of 346) with videos related to

Sort By:
Pageof 35
Leukemia|April 12, 2022
Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinibYuya Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Cancer|April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinibKiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2024
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeOren Pasvolsky, Rima M Saliba, Uday R Popat, et al.
Blood Cancer Journal|May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotypeBachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
Cancer|October 12, 2018
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageElias Jabbour, Koji Sasaki, Farhad Ravandi, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
The Lancet. Haematology|September 20, 2024
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trialNicholas J Short, Daniel Nguyen, Elias Jabbour, et al.
American Journal of Hematology|April 24, 2026
Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score AnalysisKoji Sasaki, Hagop Kantarjian, Caitlin R Rausch, et al.
Blood Advances|November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemiaNicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Pageof 35